fluoxetine has been researched along with dov 216303 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, JW; Chung, CM; Kim, HH; Lee, HY; Lee, KH; Min, KH; Nam, HS; Park, CE; Ryu, EJ; Shin, YJ; Yoon, HJ | 1 |
| Bush, LR; Campbell, UC; Engel, SR; Hardy, LW; Hewitt, MC; Koch, P; Ma, J; Malcolm, SC; Saraswat, LD; Schreiber, R; Shao, L; Spear, KL; Spicer, NA; Varney, MA; Wang, F | 1 |
| Cheon, SH; Choi, K; Hahn, HG; Han, M; Song, C; Yun, J | 1 |
3 other study(ies) available for fluoxetine and dov 216303
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Antidepressive Agents; Cell Line; CHO Cells; Cricetinae; Cricetulus; Dopamine; Humans; Mice; Neurotransmitter Uptake Inhibitors; Norepinephrine; Propylamines; Rats; Serotonin; Tetrazoles | 2010 |
Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Mice; Naphthalenes; Neurotransmitter Uptake Inhibitors; Norepinephrine; Serotonin | 2011 |
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
Topics: Azetidines; Biological Transport; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Phenyl Ethers; Plasma Membrane Neurotransmitter Transport Proteins; Serotonin; Structure-Activity Relationship | 2014 |